From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.

Andrea Harrer; Georg Pilz; Katrin Oppermann; Marlene Sageder; Shahrzad Afazel; Elisabeth Haschke-Becher; Theo Rispens; Annick de Vries; Mark R. McCoy; Vlado Stevanovic; Wolfgang Hitzl; Eugen Trinka; Jörg Kraus; Johann Sellner; Peter Wipfler

doi:10.1016/j.clim.2017.01.001

From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.

Andrea Harrer^* (First author)
, Georg Pilz (Co-author)
, Katrin Oppermann (Co-author)
, Marlene Sageder
, Shahrzad Afazel
, Elisabeth Haschke-Becher (Co-author)
, Theo Rispens
, Annick de Vries
, Mark R. McCoy (Co-author)
, Vlado Stevanovic
, Wolfgang Hitzl (Co-author)
, Eugen Trinka (Co-author)
, Jörg Kraus (Co-author)
, Johann Sellner (Co-author)
, Peter Wipfler (Last author)

^*Corresponding author for this work

Research output: Contribution to journal › Original Article › peer-review

6 Citations (Web of Science)

Original language	English
Pages (from-to)	87-93
Journal	CLINICAL IMMUNOLOGY
Volume	176
DOIs	https://doi.org/10.1016/j.clim.2017.01.001
Publication status	Published - 2017

Keywords

RELAPSING MULTIPLE-SCLEROSIS
PLACEBO-CONTROLLED TRIAL
DISEASE-ACTIVITY
ORAL FINGOLIMOD
FTY720
IMMUNE
TIME
SATURATION
WITHDRAWAL
EFFICACY

Access to Document

10.1016/j.clim.2017.01.001

Cite this

Harrer, A., Pilz, G., Oppermann, K., Sageder, M., Afazel, S., Haschke-Becher, E., Rispens, T., de Vries, A., McCoy, M. R., Stevanovic, V., Hitzl, W., Trinka, E., Kraus, J., Sellner, J., & Wipfler, P. (2017). From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch. CLINICAL IMMUNOLOGY , 176, 87-93. https://doi.org/10.1016/j.clim.2017.01.001

Harrer, Andrea ; Pilz, Georg ; Oppermann, Katrin et al. / From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch. In: CLINICAL IMMUNOLOGY 2017 ; Vol. 176. pp. 87-93.

@article{656ec137adc3401eb63185574ec5c80b,

title = "From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.",

keywords = "RELAPSING MULTIPLE-SCLEROSIS, PLACEBO-CONTROLLED TRIAL, DISEASE-ACTIVITY, ORAL FINGOLIMOD, FTY720, IMMUNE, TIME, SATURATION, WITHDRAWAL, EFFICACY",

author = "Andrea Harrer and Georg Pilz and Katrin Oppermann and Marlene Sageder and Shahrzad Afazel and Elisabeth Haschke-Becher and Theo Rispens and \{de Vries\}, Annick and McCoy, \{Mark R.\} and Vlado Stevanovic and Wolfgang Hitzl and Eugen Trinka and J{\"o}rg Kraus and Johann Sellner and Peter Wipfler",

note = "Harrer, Pilz, Oppermann, Sageder, Trinka, Sellner, Wipfler: Paracelsus Med Univ Salzburg, Dept Neurol, Salzburg, Austria; Afazel, Haschke-Becher, Kraus: Paracelsus Med Univ Salzburg, Dept Lab Med, Salzburg, Austria; McCoy, Stevanovic: Paracelsus Med Univ Salzburg, Div Neuroradiol, Salzburg, Austria; Hitzl: Paracelsus Med Univ Salzburg, Res Off, Biostat, Salzburg, Austria; Kraus: Paracelsus Med Univ Salzburg, Res Inst Neurointervent, Salzburg, Austria",

year = "2017",

doi = "10.1016/j.clim.2017.01.001",

language = "English",

volume = "176",

pages = "87--93",

journal = "CLINICAL IMMUNOLOGY ",

issn = "1521-6616",

}

Harrer, A , Pilz, G, Oppermann, K, Sageder, M, Afazel, S, Haschke-Becher, E, Rispens, T, de Vries, A, McCoy, MR, Stevanovic, V, Hitzl, W , Trinka, E , Kraus, J, Sellner, J & Wipfler, P 2017, 'From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.', CLINICAL IMMUNOLOGY , vol. 176, pp. 87-93. https://doi.org/10.1016/j.clim.2017.01.001

From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch. / Harrer, Andrea (First author); Pilz, Georg (Co-author); Oppermann, Katrin (Co-author) et al.
In: CLINICAL IMMUNOLOGY , Vol. 176, 2017, p. 87-93.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.

AU - Harrer, Andrea

AU - Pilz, Georg

AU - Oppermann, Katrin

AU - Sageder, Marlene

AU - Afazel, Shahrzad

AU - Haschke-Becher, Elisabeth

AU - Rispens, Theo

AU - de Vries, Annick

AU - McCoy, Mark R.

AU - Stevanovic, Vlado

AU - Hitzl, Wolfgang

AU - Trinka, Eugen

AU - Kraus, Jörg

AU - Sellner, Johann

AU - Wipfler, Peter

N1 - Harrer, Pilz, Oppermann, Sageder, Trinka, Sellner, Wipfler: Paracelsus Med Univ Salzburg, Dept Neurol, Salzburg, Austria; Afazel, Haschke-Becher, Kraus: Paracelsus Med Univ Salzburg, Dept Lab Med, Salzburg, Austria; McCoy, Stevanovic: Paracelsus Med Univ Salzburg, Div Neuroradiol, Salzburg, Austria; Hitzl: Paracelsus Med Univ Salzburg, Res Off, Biostat, Salzburg, Austria; Kraus: Paracelsus Med Univ Salzburg, Res Inst Neurointervent, Salzburg, Austria

PY - 2017

Y1 - 2017

KW - RELAPSING MULTIPLE-SCLEROSIS

KW - PLACEBO-CONTROLLED TRIAL

KW - DISEASE-ACTIVITY

KW - ORAL FINGOLIMOD

KW - FTY720

KW - IMMUNE

KW - TIME

KW - SATURATION

KW - WITHDRAWAL

KW - EFFICACY

U2 - 10.1016/j.clim.2017.01.001

DO - 10.1016/j.clim.2017.01.001

M3 - Original Article

C2 - 28108364

SN - 1521-6616

VL - 176

SP - 87

EP - 93

JO - CLINICAL IMMUNOLOGY

JF - CLINICAL IMMUNOLOGY

ER -

Harrer A , Pilz G, Oppermann K, Sageder M, Afazel S, Haschke-Becher E et al. From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch. CLINICAL IMMUNOLOGY . 2017;176:87-93. doi: 10.1016/j.clim.2017.01.001